Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Cardiac, Endocrine, Metabolic, and Motoric Effects in a Randomized, Double-Blind, Placebo-Controlled Study.
AUTHORS
Mischoulon
D ,
Shelton
RC ,
Baer
L ,
Bobo
WV ,
Curren
L ,
Fava
M ,
Papakostas
GI ,
. The Journal of clinical psychiatry. 2016 11 8; ().
- PMID: 27835715 [PubMed].
ABSTRACT
To examine motoric, cardiovascular, endocrine, and metabolic effects of adjunctive ziprasidone in adults with major depressive disorder (MDD) and prior nonresponse to 8 weeks of open-label escitalopram.
To examine motoric, cardiovascular, endocrine, and metabolic effects of adjunctive ziprasidone in adults with major depressive disorder (MDD) and prior nonresponse to 8 weeks of open-label escitalopram.
Tags: Alumni Publications 2016